Compare Progressive Corp (PGR) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Progressive Corp trades at $218.32 (market cap $126.95B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Progressive Corp is far larger — about 2.2× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| PGR | TAK | |
|---|---|---|
Market Cap | $126.95B | $58.74B |
Volume | 2,749,438 | 3,110,994 |
Sector | Financials | Health |
52-Week High | $242.16 | $19.05 |
52-Week Low | $190.40 | $13.23 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $135.16B | $86.65B |
Dividend Yield | 0.18% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive Corporation (PGR) trades at $214.12, up 0.98% with a bullish technical outlook. The stock shows strong fundamentals with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Valuation metrics appear reasonable with P/E of 10.74 and ROE of 34.94%. Recent earnings beat expectations in Q2 2026, and analyst consensus targets $222.23.
PGR presents a compelling investment case with consistent revenue growth and strong profitability. However, investors face risks from intensifying auto insurance competition and potential margin pressure. The stock's current price near resistance levels suggests limited near-term upside despite positive analyst sentiment.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
